Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.

Kharfan-Dabaja MA, Jain MD, Aulakh S, Ayala E, Zubair AC, Tun HW, Liu HD, Locke FL, Chavez JC.

Am J Hematol. 2019 Jun 18. doi: 10.1002/ajh.25560. [Epub ahead of print] No abstract available.

PMID:
31211433
2.

Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma.

Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ.

Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30819-3. doi: 10.1016/j.ijrobp.2019.05.065. [Epub ahead of print]

PMID:
31175906
3.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

PMID:
30865922
4.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

5.

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.

Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21.

PMID:
30579965
6.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.

7.

Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.

Dholaria BR, Bachmeier CA, Locke F.

BioDrugs. 2019 Feb;33(1):45-60. doi: 10.1007/s40259-018-0324-z. Review.

PMID:
30560413
8.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS.

Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

PMID:
30518502
9.

Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary.

Locke FL, Jain MD.

Clin Adv Hematol Oncol. 2018 Aug;16 Suppl 14(8):20-23. No abstract available.

PMID:
30300338
10.

CAR T cell therapy for B-cell lymphomas.

Chavez JC, Locke FL.

Best Pract Res Clin Haematol. 2018 Jun;31(2):135-146. doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11. Review.

PMID:
29909914
11.

Hepatic veno-occlusive disease following sirolimus-based immune suppression.

Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J.

Bone Marrow Transplant. 2019 Jan;54(1):85-89. doi: 10.1038/s41409-018-0233-2. Epub 2018 Jun 12.

PMID:
29895929
12.

Advances in aggressive lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary.

Locke FL, Haroun F.

Clin Adv Hematol Oncol. 2018 Feb;16 Suppl 5(2):19-23. No abstract available.

PMID:
29742098
13.

Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.

Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C.

Bone Marrow Transplant. 2018 Nov;53(11):1434-1444. doi: 10.1038/s41409-018-0163-z. Epub 2018 Apr 18.

PMID:
29670210
14.

CAR T-Cell Therapy in Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Go WY.

N Engl J Med. 2018 Mar 15;378(11):1065. doi: 10.1056/NEJMc1800913. No abstract available.

PMID:
29539277
15.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13. No abstract available.

PMID:
29434334
16.

Off-the-shelf TCR for graft-versus-leukemia without GVHD.

Locke FL, Anasetti C.

Blood. 2018 Jan 4;131(1):5-7. doi: 10.1182/blood-2017-11-812990. No abstract available.

17.

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.

Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JLM, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C.

Haematologica. 2018 Mar;103(3):531-539. doi: 10.3324/haematol.2017.171199. Epub 2017 Dec 14.

18.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

19.

Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience.

Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e35-e39. doi: 10.1016/j.clml.2017.10.002. Epub 2017 Oct 12.

PMID:
29126867
20.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):400-405. doi: 10.1016/j.bbmt.2017.09.022. Epub 2017 Oct 13.

21.

A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction.

Chavez JC, Locke FL.

Mol Ther. 2017 Oct 4;25(10):2241-2243. doi: 10.1016/j.ymthe.2017.09.005. Epub 2017 Sep 21. No abstract available.

22.

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.

PMID:
28925994
23.

Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary.

Locke FL.

Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 8(8):16-19. No abstract available.

PMID:
28837125
24.

Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap.

Locke FL, Anasetti C; Moffitt Immunotherapy Working Group and the Immune Cell Therapy (ICE-T) Program.

J Immunother Cancer. 2017 Jul 18;5(1):59. doi: 10.1186/s40425-017-0265-y.

25.

Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.

Hampras SS, Locke FL, Chavez JC, Patel NS, Giuliano AR, Miller K, Gheit T, Tommasino M, Rollison DE.

Leuk Lymphoma. 2018 Apr;59(4):911-917. doi: 10.1080/10428194.2017.1342822. Epub 2017 Jul 6.

26.

Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy.

Locke FL, Davila ML.

Expert Opin Biol Ther. 2017 Jun;17(6):659-661. doi: 10.1080/14712598.2017.1322953. No abstract available.

PMID:
28454503
27.

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J.

Bone Marrow Transplant. 2017 Jul;52(7):1003-1009. doi: 10.1038/bmt.2017.63. Epub 2017 Apr 3.

PMID:
28368376
28.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY.

Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4.

29.

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C.

Haematologica. 2017 May;102(5):948-957. doi: 10.3324/haematol.2016.153072. Epub 2017 Jan 19.

30.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C.

Biol Blood Marrow Transplant. 2017 Mar;23(3):405-411. doi: 10.1016/j.bbmt.2016.12.624. Epub 2016 Dec 19.

31.

Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation.

Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2201-2207. doi: 10.1016/j.bbmt.2016.09.014. Epub 2016 Sep 19.

32.

Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J.

Leuk Res. 2016 Aug;47:78-83. doi: 10.1016/j.leukres.2016.05.012. Epub 2016 May 17.

PMID:
27285853
33.

New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?

Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML.

Bone Marrow Transplant. 2016 Sep;51(9):1256-8. doi: 10.1038/bmt.2016.105. Epub 2016 Apr 18. No abstract available.

PMID:
27088383
34.

Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.

Evaristo C, Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML.

J Immunol. 2016 Apr 1;196(7):2933-8. doi: 10.4049/jimmunol.1501144. Epub 2016 Feb 22.

35.

IMMEDIATE EFFECTS OF A DYNAMIC ROTATION-SPECIFIC WARM-UP ON X-FACTOR AND X-FACTOR STRETCH IN THE AMATEUR GOLFER.

Henry E, Berglund K, Millar L, Locke F.

Int J Sports Phys Ther. 2015 Dec;10(7):998-1006.

36.

Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma.

Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C.

Bone Marrow Transplant. 2016 Feb;51(2):291-4. doi: 10.1038/bmt.2015.239. Epub 2015 Oct 12. No abstract available.

37.

Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion.

Zimmerman A, Locke FL, Emole J, Rosa M, Horna P, Hoover S, Dayicioglu D.

Cancer Control. 2015 Jul;22(3):369-73.

PMID:
26351895
38.

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.

Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2015 Nov;50(11):1487-9. doi: 10.1038/bmt.2015.192. Epub 2015 Aug 24. No abstract available.

39.

Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.

Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C.

J Immunother Cancer. 2015 May 19;3:20. doi: 10.1186/s40425-015-0065-1. eCollection 2015.

40.

An update on current and prospective immunotherapies for chronic lymphocytic leukemia.

Emole JN, Locke FL, Pinilla-Ibarz J.

Immunotherapy. 2015;7(4):455-66. doi: 10.2217/imt.15.14. Review.

PMID:
25917633
41.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Haematologica. 2015 Jul;100(7):970-7. doi: 10.3324/haematol.2015.123588. Epub 2015 Apr 3.

42.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1074-82. doi: 10.1016/j.bbmt.2015.03.014. Epub 2015 Mar 21.

43.

Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.

Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):335-40. doi: 10.1016/j.clml.2014.12.016. Epub 2015 Jan 7.

PMID:
25659459
44.

Merkel cell carcinoma and immunosuppression: what we still need to know.

Locke FL, Rollison DE, Sondak VK.

J Natl Cancer Inst. 2015 Jan 8;107(2). pii: dju422. doi: 10.1093/jnci/dju422. Print 2015 Feb. No abstract available.

PMID:
25575646
45.

Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL.

Leuk Res. 2014 Oct;38(10):1165-72. doi: 10.1016/j.leukres.2014.04.006. Epub 2014 Apr 28.

46.

Immunotherapy strategies for multiple myeloma: the present and the future.

Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA.

Immunotherapy. 2013 Sep;5(9):1005-20. doi: 10.2217/imt.13.97. Review.

47.

Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.

Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C.

Bone Marrow Transplant. 2014 Jan;49(1):11-6. doi: 10.1038/bmt.2013.121. Epub 2013 Sep 2.

PMID:
23995098
48.

Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.

Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF.

J Immunol. 2013 Aug 15;191(4):1677-85. doi: 10.4049/jimmunol.1202018. Epub 2013 Jul 12.

49.

A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.

Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W.

Bone Marrow Transplant. 2013 Nov;48(11):1437-43. doi: 10.1038/bmt.2013.79. Epub 2013 Jun 17.

50.

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1087-93. doi: 10.1016/j.bbmt.2013.04.020. Epub 2013 Apr 28.

Supplemental Content

Support Center